Navigation Links
Exenatide Once Monthly Showed Positive Results in Phase 2 Study
Date:3/10/2011

s a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego.

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes' robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Mass., Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.

This press release contains forward-looking statements about Amylin, Lilly and Alkermes. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYDUREON may not be approved by the FDA and/or the European Commission as soon as anticipated or at all; the comp
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
2. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
3. Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
4. Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
5. New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
6. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
7. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
8. Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
9. BioProcess International Launches Monthly Asia-Pacific eNewsletter
10. Technology PR Boutique Launches PRTechConnect to Help Tech Startups Restart Economy with Industry's First $999 Monthly Service
11. RSB Spine, LLC, Announces Record Second-Quarter 2010 Revenue and Monthly Sales Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Proove ... new data on the relationship of genetics and hypertension at the International ... Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview ...
(Date:8/26/2015)... 2015  The Diabetes Research Institute (DRI), a ... Miller School of Medicine, announced today that the ... for the first time a novel transplant technique ... approved Phase I/II study builds upon decades of ... important first step toward the development of the ...
(Date:8/26/2015)... , August 26, 2015 After litigating ... Europlasma NV relating to P2i United States ... their dispute in the United States ... the part of either party. As a result of the ... of California dismissed the case without ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... tissue lesions are cancerous is described by University of Illinois researchers in the ... optics and photonics. , In “ Breast cancer diagnosis using spatial light interference ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4
... -Now for Exclusion of Venous Thromboembolism-, LEXINGTON, ... that the US Food and Drug Administration (FDA) ... for the HemosIL D-Dimer,assay to exclude venous thromboembolism ... and pulmonary embolism (PE), when used in,conjunction with ...
... Performance - Net Profit Up 16.8% at Constant Exchange Rates - Essilor Launches a Share Buyback Program ... the six months,ended June 30, 2008., EUR millions First-half 2008 ... ... at constant ...
... UK,s National Physical Laboratory (NPL) to survey nanotechnology capabilities ... to identify the next generation of nano and smart ... , "Advances in nanotechnology are crucial to Europe,s space ... nanomaterials group at NPL, who will be the principal ...
Cached Biology Technology:Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay 2Essilor's First-Half 2008 Results 2Essilor's First-Half 2008 Results 3Essilor's First-Half 2008 Results 4Essilor's First-Half 2008 Results 5Essilor's First-Half 2008 Results 6Essilor's First-Half 2008 Results 7Essilor's First-Half 2008 Results 8
(Date:8/17/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 2015. The new marketing campaign is being spearheaded by ... Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... retail driven marketing and brand awareness and has a ...
(Date:8/11/2015)... 11, 2015 Today, ZUK announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... latest American Chemical Society (ACS) Weekly PressPac from the ... 34 peer-reviewed journals and Chemical & Engineering News.,Please credit ... the source for this information. PressPac Archive: ... 1 FOR IMMEDIATE RELEASE, Solving the mystery of what ...
... (April 12, 2009) In certain respects, cells are ... have lots of components, but they also have lots ... are studied in aggregate (conservatives, liberals, atheists, evangelicals), they ... looked at one person at a time, individuals often ...
... a result of exposure to ionizing radiation, they must make ... for death, a process called apoptosis. It,s a ... involving what might be described metaphorically as a network of ... the cell nucleus. In intricate ways, cells orchestrate a ...
Cached Biology News:American Chemical Society Weekly PressPac -- April 8, 2009 2American Chemical Society Weekly PressPac -- April 8, 2009 3American Chemical Society Weekly PressPac -- April 8, 2009 4American Chemical Society Weekly PressPac -- April 8, 2009 5American Chemical Society Weekly PressPac -- April 8, 2009 6American Chemical Society Weekly PressPac -- April 8, 2009 7American Chemical Society Weekly PressPac -- April 8, 2009 8American Chemical Society Weekly PressPac -- April 8, 2009 9American Chemical Society Weekly PressPac -- April 8, 2009 10American Chemical Society Weekly PressPac -- April 8, 2009 11For cancer cells, genetics alone is poor indicator for drug response 2For cancer cells, genetics alone is poor indicator for drug response 3CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 2CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 3CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 4
MagSi monodispers, magnetic silica particles with modified surface for SO3 coupling chemistry....
Recognizes a full-length CLC-2 voltage-gated Cl- protein and not with other known proteins tested so far....
Monoclonal Anti-Gα o purified immunoglobulin buffered aqueous solution Solution in phosphate buffered saline pH 7.4, containing 0.08% sodium azide. partially purified bovine brain Gα O ...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Biology Products: